Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High – Here’s What Happened

Posted by Francis Steltz on Jun 24th, 2026

Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $17.50 and last traded at $17.18, with a volume of 2337825 shares. The stock had previously closed at $15.88.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. UBS Group set a $26.00 price target on shares of Relay Therapeutics in a research report on Tuesday, May 19th. Guggenheim increased their price objective on shares of Relay Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Oppenheimer raised their target price on shares of Relay Therapeutics from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Tuesday, April 28th. JonesTrading upgraded shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, HC Wainwright upped their price target on shares of Relay Therapeutics from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Relay Therapeutics has a consensus rating of “Buy” and a consensus price target of $23.30.

Read Our Latest Analysis on Relay Therapeutics

Relay Therapeutics Price Performance

The company has a market cap of $3.45 billion, a price-to-earnings ratio of -11.51 and a beta of 1.75. The company’s 50-day simple moving average is $14.34 and its 200-day simple moving average is $10.97.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. Equities analysts predict that Relay Therapeutics, Inc. will post -1.55 EPS for the current fiscal year.

Insider Buying and Selling

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 17,717 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $12.86, for a total value of $227,840.62. Following the transaction, the chief financial officer owned 195,178 shares in the company, valued at $2,509,989.08. The trade was a 8.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last quarter, insiders have sold 40,449 shares of company stock valued at $532,889. Insiders own 5.04% of the company’s stock.

Institutional Trading of Relay Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in Relay Therapeutics by 591.7% during the 4th quarter. SG Americas Securities LLC now owns 220,949 shares of the company’s stock valued at $1,869,000 after purchasing an additional 189,004 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in Relay Therapeutics during the 3rd quarter worth approximately $399,000. Sanctuary Advisors LLC acquired a new position in shares of Relay Therapeutics in the 4th quarter valued at approximately $1,203,000. Commodore Capital LP raised its position in shares of Relay Therapeutics by 27.3% in the 3rd quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock valued at $88,740,000 after purchasing an additional 3,650,000 shares in the last quarter. Finally, Mayport LLC purchased a new position in shares of Relay Therapeutics during the 3rd quarter valued at approximately $259,000. 96.98% of the stock is owned by hedge funds and other institutional investors.

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.